Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: Findings in 42 patients followed for 1-16 years

Cristina Ferrari, M. Serena Benassi, Francesca Ponticelli, Gabriella Gamberi, Paola Ragazzini, Laura Pazzaglia, Alba Balladelli, Franco Bertoni, Piero Picci

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: The activity of matrix metalloproteinases (MMPs) in degrading extracellular matrix is controlled by activation of proenzymes and inhibition of MMP tissue inhibitors (TIMPs). Patients and methods: To assess the proteolytic cascade imbalance in malignancy progression, tissue expression and serum levels of MMP-2, MMP-9 and of their inhibitors TIMP-2 and TIMP-1 respectively were evaluated in 42 selected patients with high-grade osteosarcoma (OS). MMP-2, MMP-9, TIMP-2 and TIMP-1 were studied in biopsies by immunohistochemistry and in serum by ELISA test. Patients were subdivided into 3 groups according to their follow up: continuously disease-free, diagnosis of metastasis during follow-up, and metastasis at diagnosis. Results: Immunohistochemistry demonstrated an imbalance between MMPs and TIMPs, with a more evident role for MMP-9 than for MMP-2 in tumor progression. TIMP-1 inhibitor in plasma was higher in patients with osteosarcoma than in a control group. This high value of TIMP-1 was particularly evident in the group of patients who later developed metastases and/or local recurrences, and in those with metastases at diagnosis. Interpretation: Our findings confirm the protective action of TIMP-1, as MMP inhibitor, but also show its activity as a growth factor underlining its multifunctional role in OS.

Original languageEnglish
Pages (from-to)487-491
Number of pages5
JournalActa Orthopaedica Scandinavica
Volume75
Issue number4
DOIs
Publication statusPublished - Aug 2004

Fingerprint

Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinase 9
Osteosarcoma
Matrix Metalloproteinase 2
Neoplasm Metastasis
Tissue Inhibitor of Metalloproteinase-2
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Immunohistochemistry
Enzyme Precursors
Serum
Extracellular Matrix
Neoplasms
Intercellular Signaling Peptides and Proteins
Enzyme-Linked Immunosorbent Assay
Biopsy
Recurrence
Control Groups

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Cite this

Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma : Findings in 42 patients followed for 1-16 years. / Ferrari, Cristina; Benassi, M. Serena; Ponticelli, Francesca; Gamberi, Gabriella; Ragazzini, Paola; Pazzaglia, Laura; Balladelli, Alba; Bertoni, Franco; Picci, Piero.

In: Acta Orthopaedica Scandinavica, Vol. 75, No. 4, 08.2004, p. 487-491.

Research output: Contribution to journalArticle

@article{c06db6a87db04f709817f2dc801eb38a,
title = "Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: Findings in 42 patients followed for 1-16 years",
abstract = "Background: The activity of matrix metalloproteinases (MMPs) in degrading extracellular matrix is controlled by activation of proenzymes and inhibition of MMP tissue inhibitors (TIMPs). Patients and methods: To assess the proteolytic cascade imbalance in malignancy progression, tissue expression and serum levels of MMP-2, MMP-9 and of their inhibitors TIMP-2 and TIMP-1 respectively were evaluated in 42 selected patients with high-grade osteosarcoma (OS). MMP-2, MMP-9, TIMP-2 and TIMP-1 were studied in biopsies by immunohistochemistry and in serum by ELISA test. Patients were subdivided into 3 groups according to their follow up: continuously disease-free, diagnosis of metastasis during follow-up, and metastasis at diagnosis. Results: Immunohistochemistry demonstrated an imbalance between MMPs and TIMPs, with a more evident role for MMP-9 than for MMP-2 in tumor progression. TIMP-1 inhibitor in plasma was higher in patients with osteosarcoma than in a control group. This high value of TIMP-1 was particularly evident in the group of patients who later developed metastases and/or local recurrences, and in those with metastases at diagnosis. Interpretation: Our findings confirm the protective action of TIMP-1, as MMP inhibitor, but also show its activity as a growth factor underlining its multifunctional role in OS.",
author = "Cristina Ferrari and Benassi, {M. Serena} and Francesca Ponticelli and Gabriella Gamberi and Paola Ragazzini and Laura Pazzaglia and Alba Balladelli and Franco Bertoni and Piero Picci",
year = "2004",
month = "8",
doi = "10.1080/00016470410001295",
language = "English",
volume = "75",
pages = "487--491",
journal = "Acta Orthopaedica Scandinavica",
issn = "0001-6470",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma

T2 - Findings in 42 patients followed for 1-16 years

AU - Ferrari, Cristina

AU - Benassi, M. Serena

AU - Ponticelli, Francesca

AU - Gamberi, Gabriella

AU - Ragazzini, Paola

AU - Pazzaglia, Laura

AU - Balladelli, Alba

AU - Bertoni, Franco

AU - Picci, Piero

PY - 2004/8

Y1 - 2004/8

N2 - Background: The activity of matrix metalloproteinases (MMPs) in degrading extracellular matrix is controlled by activation of proenzymes and inhibition of MMP tissue inhibitors (TIMPs). Patients and methods: To assess the proteolytic cascade imbalance in malignancy progression, tissue expression and serum levels of MMP-2, MMP-9 and of their inhibitors TIMP-2 and TIMP-1 respectively were evaluated in 42 selected patients with high-grade osteosarcoma (OS). MMP-2, MMP-9, TIMP-2 and TIMP-1 were studied in biopsies by immunohistochemistry and in serum by ELISA test. Patients were subdivided into 3 groups according to their follow up: continuously disease-free, diagnosis of metastasis during follow-up, and metastasis at diagnosis. Results: Immunohistochemistry demonstrated an imbalance between MMPs and TIMPs, with a more evident role for MMP-9 than for MMP-2 in tumor progression. TIMP-1 inhibitor in plasma was higher in patients with osteosarcoma than in a control group. This high value of TIMP-1 was particularly evident in the group of patients who later developed metastases and/or local recurrences, and in those with metastases at diagnosis. Interpretation: Our findings confirm the protective action of TIMP-1, as MMP inhibitor, but also show its activity as a growth factor underlining its multifunctional role in OS.

AB - Background: The activity of matrix metalloproteinases (MMPs) in degrading extracellular matrix is controlled by activation of proenzymes and inhibition of MMP tissue inhibitors (TIMPs). Patients and methods: To assess the proteolytic cascade imbalance in malignancy progression, tissue expression and serum levels of MMP-2, MMP-9 and of their inhibitors TIMP-2 and TIMP-1 respectively were evaluated in 42 selected patients with high-grade osteosarcoma (OS). MMP-2, MMP-9, TIMP-2 and TIMP-1 were studied in biopsies by immunohistochemistry and in serum by ELISA test. Patients were subdivided into 3 groups according to their follow up: continuously disease-free, diagnosis of metastasis during follow-up, and metastasis at diagnosis. Results: Immunohistochemistry demonstrated an imbalance between MMPs and TIMPs, with a more evident role for MMP-9 than for MMP-2 in tumor progression. TIMP-1 inhibitor in plasma was higher in patients with osteosarcoma than in a control group. This high value of TIMP-1 was particularly evident in the group of patients who later developed metastases and/or local recurrences, and in those with metastases at diagnosis. Interpretation: Our findings confirm the protective action of TIMP-1, as MMP inhibitor, but also show its activity as a growth factor underlining its multifunctional role in OS.

UR - http://www.scopus.com/inward/record.url?scp=4444320486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444320486&partnerID=8YFLogxK

U2 - 10.1080/00016470410001295

DO - 10.1080/00016470410001295

M3 - Article

C2 - 15370596

AN - SCOPUS:4444320486

VL - 75

SP - 487

EP - 491

JO - Acta Orthopaedica Scandinavica

JF - Acta Orthopaedica Scandinavica

SN - 0001-6470

IS - 4

ER -